{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-343482","form_type":"8-K","ticker":"MREO","cik":"0001719714","company_name":"Mereo BioPharma Group plc","filed_at":"2026-08-11T12:07:21+00:00","discovered_at":"2026-08-11T12:10:07.150148+00:00","generated_at":"2026-08-11T12:10:18.195479+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Mereo, Sentynl sign option/license deal for alvelestat in AATD-LD; up to $40M upfront, $435M milestones","bullets":["Non-refundable option fee; on exercise $40M upfront/R&D, up to $435M milestones, double-digit tiered royalties on US sales.","Sentynl gets US commercial and global manufacturing rights; Mereo keeps rest-of-world rights and leads global Phase 3.","Alvelestat is a neutrophil elastase inhibitor; potential first oral treatment for AATD-LD affecting ~50k-80k US patients.","Phase 3 could start early 2027; backed by positive efficacy data from two Phase 2 studies.","Agreement dated Aug 11, 2026; parties to collaborate on manufacturing and Phase 3 design during option period."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-343482","json":"https://secwatch.observer/filing/0001193125-26-343482.json","markdown":"https://secwatch.observer/filing/0001193125-26-343482.md","text":"https://secwatch.observer/filing/0001193125-26-343482.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719714/000119312526343482/0001193125-26-343482-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719714/000119312526343482/mreo-20260811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T12:10:18.195479+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}